Quality assessment | No. of patients | Effect | Quality | Importance | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | MIH | Control | Relative (95 % CI) | Absolute (95 % CI) | ||
Mortality (follow-up 180 days or hospital discharge) | ||||||||||||
5 | Randomised trials | Seriousa | Seriousb | Seriousc | Not serious | None | 332/691 (48.0 %) | 343/672 (51.0 %) | RR 0.94 (0.84–1.04) | 31 fewer per 1000 (from 20 more to 82 fewer) | ⨁◯◯◯ VERY LOWa b c | CRITICAL |
55.1 % | 33 fewer per 1000 (from 22 more to 88 fewer) | |||||||||||
Neurological outcome (follow-up 180 days or hospital discharge) | ||||||||||||
6 | Randomised trials | Seriousa | Seriousb | Seriousc | Not serious | None | 381/722 (52.8 %) | 391/687 (56.9 %) | RR 0.83 (0.68–1.01) | 97 fewer per 1000 (from 6 more to 182 fewer) | ⨁◯◯◯ VERY LOWa b c | CRITICAL |
67.1 % | 114 fewer per 1000 (from 7 more to 215 fewer) |